Search Results
Your search for ,maY matches 17054 pages
Showing 11651 - 11700Treatment Update in Gastric, Pancreatic, and Colorectal Cancers
Although new gastrointestinal cancers are on the rise, advancements in their treatment, as well as the upcoming results of perioperative trials, could prove to be “clinical practice game-changers,” declared Thomas J. George, Jr, MD, FACP, at the 2016 Community Oncology Conference in Orlando,...
Expert Point of View: Samir Gupta, MD
Samir Gupta, MD, Associate Professor of Medicine at the University of California San Diego, who has led trials of colorectal cancer screening, commented on this study for The ASCO Post. Although there are approximately 138,000 new colorectal cancer diagnoses a year in the United States, only...
Young-Onset Colorectal Cancer Diagnoses Rising
Colorectal cancer is being increasingly diagnosed in persons younger than age 50, the age at which colorectal cancer screening is usually initiated. According to Elie Sutton, MD, of Mount Sinai West Hospital in New York, a review of cases in the National Cancer Data Base revealed that between...
Impressive Early Data for Rovalpituzumab Tesirine in Small Cell Lung Cancer
Initial encouraging news from a first-in-human trial suggests that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may turn out to be a new option for patients with small cell lung cancer (SCLC) whose tumors overexpress delta-like protein 3 (DLL3). Study results were presented at the...
Expert Point of View: Peter C. Enzinger, MD
Not so FAST? The study discussant Peter C. Enzinger, MD, Director of the Center for Esophageal and Gastric Cancer at Dana-Farber/Brigham and Women’s Cancer Center, Boston, viewed the findings of the FAST trial as promising but voiced several considerations, as did Gulam A. Manji, MD, PhD,...
Expert Point of View: Sumanta K. Pal, MD, and Richard L. Schilsky, MD
“This study harnesses a specific biologic marker in cancer patients and treats them accordingly using a ‘tumor-agnostic’ approach, so a patient with pancreatic cancer may get a breast cancer drug,” said Sumanta K. Pal, MD, ASCO spokesperson. Dr. Pal moderated the press conference where these data ...
Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India and South Africa. Notably, after the monthly drug price is expressed as a percentage of domestic...
CAR T-Cell Therapy Using Double Target Aimed at Solid Tumors in Preclinical Models
Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Now, in a report published...
Influence of Age and Comorbidities on Rates of Colorectal Cancer Screening in the Elderly
Colorectal cancer (CRC) is a common and costly disease, largely of the elderly, with nearly 25% of cases diagnosed among patients aged 75–84 years. However, but the guidelines for CRC screening of Americans aged 75 or older vary according to the source. In a study published by Klabunde et al...
Aggressive Treatment at the End of Life Continues to Be Common
Oncologists in the United States may need to improve their efforts to reduce unnecessary care for younger patients with terminal cancer over the last 30 days of life, based on the findings of a study reported at the 2016 ASCO Annual Meeting.1 Contrary to recommendations, aggressive care is still...
Expert Point of View: Don Dizon, MD
Don Dizon, MD, Chair of ASCO’s Cancer Communications Committee, congratulated the authors of the OV21/PETROC study. “This is another example of international collaboration. The authors looked at the role of IP therapy in women who got primary chemotherapy before surgery, and at least in this...
ASCO Releases the Updated Version of Its Value Framework
Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...
Expert Point of View: Dominique Valteau-Couanet, MD, PhD
Study discussant Dominique Valteau-Couanet, MD, PhD, of the Gustave Roussy in France, said the study was “an important step” in research, by showing “Cy-THIO/mCEM [tandem autologous stem cell transplant (ASCT) with cyclophosphamide/thiotepa followed by a modified regimen of...
For High-Risk Neuroblastoma, Two Transplants May Be Better Than One
In children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates in the ANBL0532 trial from the Children’s Oncology Group. The study was presented at the plenary session of the 2016 ASCO Annual Meeting by Julie R. Park, MD, of Seattle...
Low-Dose CT Screening May Detect New Solid Nodules and Lung Cancer Probability
As reported by Walter et al in The Lancet Oncology, incidence screening with low-dose computed tomography (CT) in high-risk individuals detected new solid nodules in approximately 5% to 7% at second and third screenings in the ongoing Dutch-Belgian NELSON trial. Larger nodule size was associated...
Patient Navigators Improve Comprehensive Cancer Center Screening Rates
A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators—individuals who assist patients in receiving health care services—may improve comprehensive cancer screening rates among patient populations not likely to...
Report Finds Families of Cancer Survivors Challenged by Intense, Episodic Caregiving Experiences
A new report shows that people caring for a loved one with cancer often have more intense, episodic caregiver responsibilities than those caring for someone with other health needs. The report, from the National Alliance for Caregiving in partnership with the National Cancer Institute and the...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
SNMMI 2016: PET/CT Imaging of Prostate Cancer With Specific Agent May Be an Accurate Prebiopsy/Preoperative Guide
With surgical removal at the frontline of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society of ...
Lifestyle Pattern May Be Associated With Cancer Risk in White Adults
In a study reported in JAMA Oncology, Song and Giovannucci found that a “healthy lifestyle pattern” was associated with a reduced risk for carcinomas among white adults. Study Details The study included data from the Nurses’ Health Study and the Health Professionals Follow-up...
Neoadjuvant Chemotherapy May Render Advanced Ovarian Cancers Responsive to Immunotherapy
Although most patients with advanced ovarian cancer initially respond to platinum-based chemotherapy, they usually relapse. According to a study by Böhm et al published in Clinical Cancer Research, neoadjuvant chemotherapy seemed to alter the immune cells in the tumors of patients with...
SNMMI 2016: A Blood-Based Multi-Transcript Test May Predict Success of Neuroendocrine Cancer Therapy
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could...
SNMMI 2016: FDG-PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a means of evaluating an immunotherapy that fights off non–small cell lung cancer (NSCLC) by strengthening a patient’s own immune system (Scientific Paper 134). Due to...
SNMMI 2016: CT-Based Lean Body Mass Calculations Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body...
Mindfulness-Based Stress-Reduction Program May Reduce Psychological and Physical Symptoms in Breast Cancer Survivors
A mindfulness-based stress-reduction program for breast cancer survivors was associated with psychological and physical symptom benefits during and at 6 weeks after intervention, according to a randomized trial reported in the Journal of Clinical Oncology by Lengacher et al. Study Details In the...
Many Family Physicians May Be Misinformed About Lung Cancer Screening
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (CT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths. Most were...
Adjuvant Chemotherapy in Early-Stage Non–Small Cell Lung Cancer Improves Overall Survival
The use of adjuvant chemotherapy in early-stage non–small cell lung cancer (NSCLC) patients improves overall survival and 5-year overall survival rates in patients with tumor sizes ranging from 3 to 7 cm. These findings were published by Morgensztern et al in the Journal of Thoracic...
ASCO 2016: Hispanic and Black Young Adults With Cancer May Be More Likely to Die of Their Disease
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented by Colton et al at the 2016 ASCO Annual Meeting (Abstract 6557). The finding is...
ASCO Releases Clinical Practice Guideline on Metastatic Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Davendra P. Sohal, MD, MPH, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of patients with metastatic pancreatic cancer. Recommendations are based on expert panel systematic review of the...
ASCO Releases Clinical Practice Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer
As reported by Edward P. Balaban, DO, of Penn State Hershey Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of locally advanced, unresectable pancreatic cancer. The recommendations are based on expert panel...
ASCO Releases Clinical Practice Guideline on Treatment of Potentially Curable Pancreatic Cancer
ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer, as reported by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, in the Journal of Clinical Oncology. The recommendations are based on expert panel systematic review of the literature...
Increased Risk for Cardiovascular Events Seen in Patients With CML Taking Tyrosine Kinase Inhibitors
Although tyrosine kinase inhibitors have dramatically increased survival for patients with chronic myeloid leukemia (CML), continuous administration of these drugs may elicit long-term toxicity, including cardiovascular adverse events. To investigate the incidence of vascular events in patients...
European Study Suggests No Benefit of GnRH in Preserving Ovarian Function and Fertility in Young Women With Lymphoma
In long-term follow-up of a European trial reported by Demeestere et al in the Journal of Clinical Oncology, gonadotropin-releasing hormone (GnRH) agonist treatment during chemotherapy in young women with lymphoma was not associated with reduced premature ovarian failure or an improved pregnancy...
ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression
In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...
FDA Approves EGFR Mutation–Detecting Blood Test for NSCLC
The U.S. Food and Drug Administration (FDA) recently approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene...
International Prognostic Index for Chronic Lymphocytic Leukemia
The International Chronic Lymphocytic Leukemia–International Prognostic Index (CLL-IPI) working group has developed an International Prognostic Index for patients with chronic lymphocytic leukemia based on a meta-analysis of individual patient data, as reported in The Lancet Oncology. The...
FOLFIRINOX in Locally Advanced Pancreatic Cancer
First-line FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin) is associated with median overall survival of approximately 2 years in patients with locally advanced pancreatic cancer, according to a systematic review and patient-level meta-analysis reported by Suker et al.1 Study ...
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...
ASCO Updates Value in Cancer Care Framework
On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms...
Breast Density Legislation: An Opportunity for Better Risk Assessment
Dense breasts are not an automatic indication for additional imaging. Instead, breast density generally provides an opportunity for improved risk assessment, according to Kevin Hughes, MD, of Massachusetts General Hospital, Boston. “More than 20 states have mandated that women be informed of...
The Best HCAHPS Score: A Rodeo Invitation
An otherwise healthy, actively working, independent 60-year-old patient came to us with a several months’ history of abdominal pain. He had been seen by other physicians prior to coming to us for a second opinion. Our workup revealed a large cystic lesion emanating from the pancreas but involving ...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Multi-Institutional Metastatic Melanoma Research Team Receives $900,000 L’Oréal Paris USA–MRA Team Science Award for Women in Scientific Research
An international, multi-institutional research team consisting of the Spanish National Cancer Research Centre (CNIO); The Wistar Institute; Cancer Research UK Edinburgh Centre; the Perelman School of Medicine at the University of Pennsylvania; and the Icahn School of Medicine at Mount Sinai has...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al,1 the report ...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 13, 2016, lenvatinib (Lenvima) was approved for use in...
Prostate Cancer: Opinions Vary on Gleason Scores and Surgery
Diagnosis and treatment of prostate cancer have been the source of heated debate for decades, most of which has centered on the clinical value of the prostate-specific antigen (PSA) test. In 2012, the U.S Preventive Services Task Force (USPSTF) gave the PSA test a D grade, which discourages many...
ASCO Submits Comments to ONC on Enhanced Oversight of the HIT Certification Program
On Monday, May 2, ASCO submitted comments to the Office of the National Coordinator (ONC) regarding the proposed Enhanced Oversight of the ONC Health Information Technology (HIT) Certification Program rule. The rule would increase ONC oversight of certified health IT, define a process for...
